= Emerging. More than 5 years before clinical availability. (19.79%)
= Expected to be clinically available in 1 to 4 years. (37.97%)
= Clinically available now. (42.25%)
MSACL 2022 : Grant

MSACL 2022 Abstract

Self-Classified Topic Area(s): Practical Training

Podium Presentation in Bonzai on Wednesday at 16:30 (Chair: TBA)

Transition Ratio Monitoring for the Masses

Russ Grant
Laboratory Corporation of America

Russell Grant (Presenter)
Labcorp

Presenter Bio: Dr Grant earned a PhD in chromatographic and mass spectrometric technologies from the University of Swansea, Wales, United Kingdom. He continued his scientific training in various industrial settings, which have included senior scientist at GSK, principal scientist at Cohesive Technologies, technical director at Eli Lilly, and director of mass spectrometry at Esoterix Endocrinology.

Dr Grant has pioneered the use of direct injection technologies, chromatographic systems multiplexing, utility of automation, and new analytical platforms for application in bioanalytical applications. His research goals are focused upon improvements in speed, sensitivity, and quality of liquid chromatography with tandem mass spectrometric (LC-MS/MS) analytical systems and assays.

Dr Grant serves as clinical chemistry chair for the American Society of Mass Spectrometry and is a member of the American Association for Clinical Chemistry

Abstract

Central to determining assay quality and results reporting apriori is the fundamental belief that one is selectively measuring the analyte of choice. The use of transition ratio monitoring, while somewhat known to many users of tandem mass spectrometry, still provides a multitude of discreet challenges in the development, use and interrogation of chromatographic data. Historical rules based review, driven by qualifier transition yield relative to the quantifier transition fails to provide the appropriate quality considerations based on meaningful data. This presentation will include an arc of developmental understanding, from initial assessments (including favoring selectivity over sensitivity), validation of ion ratio's (sample types and concentrations) and use of transition ratio's (multi-level, non-symmetrical and statistically based).

Take home "Pearls" include:
1. How to select appropriate transitions for use in transition ratio monitoring - including tools to enhance response function for low intensity transitions
2. How to improve the precision of Transition ratio's through scheduling and appropriate dwell times
3. How to design transition ratio tolerances to enhance medical utility and including when to ignore the qualifier transition.


Financial Disclosure

DescriptionY/NSource
Grantsno
SalaryyesLaboratory Corporation of America
Board Memberno
Stockyes Laboratory Corporation of America
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no